New Study Shows IV Ketamine Beats Nasal Esketamine

Study Findings Highlight Treatment Differences

A new depression study has found that patients receiving intravenous ketamine achieved remission at higher rates compared to those treated with nasal esketamine (Spravato). This research adds important data to the ongoing discussion about which ketamine-based treatment approach offers the best outcomes for treatment-resistant depression.

The study results, reported by Stock Titan in June 2026, come at a time when more patients are exploring ketamine therapy options for depression that hasn't responded to traditional antidepressants.

Understanding the Two Treatment Approaches

The comparison involves two distinct forms of ketamine therapy that differ substantially in how they're administered and experienced by patients.

Intravenous ketamine involves receiving racemic ketamine through an IV infusion, typically over 40-60 minutes in a medical setting. This approach has been used off-label for depression treatment since the early 2000s and allows for precise dosing control.

Nasal esketamine (Spravato) is FDA-approved specifically for treatment-resistant depression and is administered as a nasal spray under medical supervision. Esketamine is the S-enantiomer of ketamine, considered the more active component of the compound.

What This Means for Treatment Selection

For patients considering ketamine therapy, these findings highlight several practical considerations that go beyond just effectiveness rates.

Treatment Setting and Logistics: IV ketamine typically requires specialized clinics with infusion capabilities, while esketamine can be administered in more standard psychiatric offices. This affects accessibility and convenience, especially for patients in smaller markets.

Insurance and Cost Implications: Esketamine's FDA approval means it's more likely to be covered by insurance plans, while IV ketamine is often paid out-of-pocket. However, if IV treatment proves more effective, fewer total sessions might be needed, potentially affecting overall treatment costs.

Patient Experience Differences: The routes of administration create different treatment experiences. IV infusions typically involve longer clinic visits but may provide more controlled dosing, while nasal administration is quicker but can cause nasal irritation and has less predictable absorption.

Clinical Implications for Providers and Patients

These study results may influence how healthcare providers approach treatment planning for patients with treatment-resistant depression. The higher remission rates with IV ketamine could make it a preferred first-line ketamine therapy for some patients, particularly those who have failed multiple traditional treatments.

However, the practical realities of accessing different forms of ketamine therapy remain important factors. Patients in areas without IV ketamine clinics may still benefit significantly from nasal esketamine, and the convenience factor shouldn't be underestimated for treatment adherence.

The findings also raise questions about optimal dosing strategies and whether the differences in outcomes relate to the delivery method itself or the specific ketamine compound used (racemic vs. esketamine).

Looking Ahead: Treatment Decision Framework

For patients and providers weighing ketamine treatment options in 2026, this research suggests several decision points to consider:

Accessibility: Can the patient reasonably access both treatment types? Geographic limitations may make the choice for them.

Insurance Coverage: What are the cost implications of each option, considering both per-treatment costs and potential differences in total treatment duration?

Previous Treatment History: Patients with extensive treatment resistance might prioritize the potentially higher effectiveness of IV ketamine, while others might prefer the convenience of nasal administration.

Medical Considerations: Individual patient factors like nasal conditions, vein access, or sensitivity to different routes of administration may influence the choice.

As more comparative research emerges, the landscape for ketamine-based depression treatment continues to evolve. This study adds valuable data to help patients and providers make more informed decisions about which approach might offer the best chance of achieving remission from treatment-resistant depression.